[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rhegmatogenous-retinal-detachment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rhegmatogenous-retinal-detachment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,73,104,127,153,173,193,218,240],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100548778","phase-1-the-safety-and-efficacy-of-intravitreal-topotecan-for-the-treatment-of-proliferative-vitreoretinopathy-100548778",false,"NCT06425419","The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy","Inclusion Criteria:\n\n* Patients \\> 18 years old\n* Patients presenting with retinal detachment due with PVR (grade C or higher) or retinal detachment associated with open globe trauma\n* Patients undergoing vitrectomy or vitrectomy with scleral buckle as part of standard care.\n\nExclusion Criteria:\n\n* Patient unable to give consent\n* Patient unable to follow-up\n* Females of childbearing age who are pregnant at the time of recruitment. A pregnancy test will be done to all women of ages 18-55 prior to surgery to ensure they are not pregnant at the time of recruitment.\n* Patients with a history of tractional or exudative retinal detachment.\n* Patients with other planned ocular surgery following PPV\n* Active or chronic or recurrent uncontrolled ocular or systemic disease\n* Active or history of chronic or recurrent inflammatory eye disease\n* Diagnosis of severe nonproliferative or proliferative diabetic retinopathy or vasoproliferative disease in the operative eye\n* Signs of ocular infection at presentation in either eye\n* Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively\n* No Light Perception vision in the operative eye\n* Failure to achieve intraoperative reattachment\n* Patient with silicone oil instilled in the operative eye at time of presentation",true,"ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of this clinical trial is to evaluate the safety and efficacy of intravitreal topotecan for the treatment of patients with rhegmatogenous retinal detachment due to proliferative vitreoretinopathy (PVR) or resulting from an open globe injury, and compare the outcomes to those who do no receive intravitreal topotecan. The main objectives it aims to achieve are:\n\n* to study the safety profile of intravitreal topotecan in the treatment of PVR\n* to evaluate the efficacy of intravitreal topotecan in treating PVR.\n\nPost-consent, participants will:\n\n* undergo vitrectomy (with or without scleral buckle) as part of standard treatment for retinal detachment.\n* receive intravitreal topotecan at the time of surgery, post-operative day 7 and post-operative day 28 (if randomized to receive the medication)\n* come in at post-operative day 1, 7, 28, 56, 84, 126 and 168 to undergo a complete ophthalmic exam along with a fundus photography and optical coherence tomography of the macula, have their intraocular pressure and visual acuity measured and their adverse events monitored, if any.\n\nResearchers will compare participants who receive intravitreal topotecan for PVR to those who do not to see if there is a significant variability in recurrence of retinal detachment, rate of retinal reattachment and PVR grade 6 months after surgery.",[26,27,28],"Proliferative Vitreoretinopathy","Proliferative Vitreo-Retinopathy","Rhegmatogenous Retinal Detachment","NOT_YET_RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":20},"2026-09-01",{"date":37,"type":20},"2028-09-01",{"name":39,"class":40},"Massachusetts Eye and Ear Infirmary","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":15,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100464743","phase-4-dropless-pars-plana-vitrectomy-study-100464743","NCT05331664","Dropless Pars Plana Vitrectomy Study","DVS","Inclusion Criteria:\n\n* Primary rhegmatogenous retinal detachment (mac-on or mac-off) requiring pars plana vitrectomy (23, 25 and 27-gauge)\n\nExclusion Criteria:\n\n* Need for concomitant lensectomy or cataract surgery\n* Pars plana vitrectomy taking place more than seven days after the initial diagnosis\n* History of any prior vitreoretinal surgery (excluding laser surgery) in surgical eye\n* History of previous retinal detachment in surgical eye\n* History of ocular incisional surgery within six months of surgery (excluding laser surgery) in surgical eye\n* History of ocular laser surgery within 1 month in surgical eye\n* History of intravitreal injection within 1 month in surgical eye\n* Diagnosis of glaucoma or intraocular pressure more than 21 mmHg in either eye\n* Active or chronic or recurrent uncontrolled ocular or systemic disease\n* Active or history of chronic or recurrent inflammatory eye disease\n* Previous history of steroid response\n* Current treatment with oral, topical, or intravitreal corticosteroids\n* Presence of proliferative vitreoretinopathy at the time of diagnosis\n* Presence of giant retinal tear at the time of diagnosis\n* Diagnosis of proliferative diabetic retinopathy\n* Anterior chamber inflammation on presentation in either eye\n* Signs of ocular infection at presentation in either eye\n* Acute external ocular infections\n* Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively\n* Inability to use or apply topical eye drops\n* Requirement for silicone oil as a tamponade agent\n* Individuals with impaired decision-making capacity\n* Non-English-speaking subjects","40 Years",{"count":50,"type":20},168,[52],"PHASE4","To demonstrate that intraoperative use of subtenon triamcinolone acetonide at the time of surgery without postoperative eye drops is non-inferior to the regimen of postoperative eye drops following primary pars plana vitrectomy for retinal detachment.",[28],[56,57,58,59,60,61,62],"Vitrectomy","Dropless","Sub-tenon steroids","Postoperative","Inflammation","Randomized clinical trial","Non-inferiority trial","RECRUITING","2026-06-23",{"date":66,"type":33},"2026-06-26",{"date":68,"type":33},"2022-07-25",{"date":70,"type":20},"2027-01-30",{"name":39,"class":40},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100592779","phase-3-treatment-of-retinal-detachment-in-people-who-have-not-had-cataract-surgery-with-vitrectomy-vs-vitrectomy-and-cataract-removal-100592779","NCT06997874","Treatment of Retinal Detachment in People Who Have Not Had Cataract Surgery With Vitrectomy vs Vitrectomy and Cataract Removal","Clinical- and Cost-effectiveness, Safety and Acceptability of Sequential Vitrectomy and Cataract Surgery vs Combined Phacovitrectomy for Rhegmatogenous Retinal Detachment: Randomised Equivalence Trial","COMBAT","Inclusion Criteria:\n\n* Adults ≥50 years of age\n* Non-highly myopic (\\\u003C -6 diopters; ≤26.5 mm axial length) phakic RRD\n* Naive to previous vitreoretinal surgery\n* Pars plana vitrectomy is planned to repair their RRD\n\nExclusion Criteria:\n\n* Presence of a \"formed\u002Festablished cataract.\" A \"formed\u002Festablished cataract\" is defined as a cataract that, based on the Age-Related Eye Disease Study (AREDS) Research Group, is graded as nuclear sclerosis of \\>3 and\u002For if there is an anterior cortical cataract and\u002For a subcapsular posterior cataract involving the visual axis.\n* Pseudophakia or aphakia\n* High myopia (≥ -6 diopters; \\>26.5 mm axial length)\n* Giant retinal tear (i.e. presence of one or more retinal tears of \\>3 clock hours in size)\n* Retinal dialysis\n* Inclusion in an investigational drug study\n* Declined consent for participation","50 Years",{"count":83,"type":20},276,[85],"PHASE3","Background and study aims The retina is the layer at the back of the eye that allows us to see. Sometimes, it can detach from the wall of the eye, causing a condition called rhegmatogenous retinal detachment (RRD), which leads to vision loss and requires surgery. The most common surgery for RRD is vitrectomy, but this can lead to complications like cataracts, which worsen over time and need to be removed with another surgery. Cataract surgery involves replacing the cloudy lens with a clear artificial one. Currently, it's unclear whether it's better to perform both surgeries at the same time or separately. The COMBAT study aims to find out which approach is best by comparing the outcomes of patients who have vitrectomy alone versus those who have both surgeries (vitrectomy and cataract surgery by phacoemulsification and intraocular lens \\[IOL\\] implantation) together.\n\nWho can participate? Adults aged 50 and older who have RRD but are not highly myopic (less than -6 diopters or an axial length of 26.5 mm or less) and have not had previous vitreoretinal surgery. Participants must be scheduled for a pars plana vitrectomy to repair their RRD.\n\nWhat does the study involve? Participants will be randomly assigned to one of two groups: one group will have vitrectomy first and, if needed, cataract surgery later; the other group will have both surgeries at the same time. The study will compare their vision, the number of successful retina reattachments, health related and visual related quality of life, patient satisfaction, complications, additional surgeries and procedures, and costs.",[28],[89,90,91,92,93],"Rhegmatogenous retinal detachment","phacovitrectomy","vitrectomy","cataract","vitreoretinal surgery","2026-06-08",{"date":96,"type":33},"2026-06-10",{"date":98,"type":33},"2025-05-16",{"date":100,"type":20},"2028-05-08",{"name":102,"class":40},"Queen's University, Belfast",31,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":72},"100638194","effect-of-silicon-oil-on-retinal-electrical-functions-using-multifocal-electroretinogram-100638194","NCT07609628","Effect of Silicon Oil on Retinal Electrical Functions Using Multifocal Electroretinogram","Effect of Silicon Oil on Retinal Electrical Functions in Patients With Rhegmatogenous Retinal Detatchment Using Multifocal Electroretinogram .","SO\u002FRRD\u002FmfERG","Inclusion Criteria:\n\n\\- Patients with primary rhegmatogenous retinal detachment\n\nExclusion Criteria:\n\n* Patients with history of previous intraocular surgery.\n* Patients with combined traction-rhegmatogenous retinal detachment\n* Patients with ocular disease as glaucoma ,degenerative myopia,age related macular degeneration\n* Patients with poor fixation.\n* Uncooperative patients.\n* Patients with retinopathy.\n* emulsified SO or complicated SO removal were excluded from this study","70 Years",{"count":19,"type":20},[115],"NA","Retinal detachment is one of the leading causes for permanent vision loss.Incidence of Rheugmatogenous Retinal Detachment (RRD) about 10.5 people per 100,000 population pars plana vitrectomy is the most popular and effective surgical options.\n\nTamponade agents as silicone oils are used to restore intraocular volume and apply surface tension to the detached retinal surface Silicone oil (SO) is a liquid containing polymerized siloxane with organic side chains. It has a high thermal stability, is hydrophobic, and chemically inert. The use of silicone oils as intraocular tamponades dates from 1962.",[28],"2026-05-21",{"date":120,"type":33},"2026-05-27",{"date":122,"type":33},"2026-02-01",{"date":124,"type":20},"2026-08-01",{"name":126,"class":40},"Minia University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":72},"100518681","phase-1-topical-netarsudil-for-the-prevention-of-proliferative-vitreoretinopathy-in-patients-with-retinal-detachment-100518681","NCT06033703","Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment","Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Primary Rhegmatogenous Detachments and Retinal Detachment Due to Proliferative Vitreoretinopathy or Open-Globe Injury: A Phase I\u002FII Clinical Trial","The primary rhegmatogenous detachment cohort will have the following selection criteria:\n\nInclusion criteria:\n\n* Patients \\> 18 years old\n* Patients presenting for primary rhegmatogenous retinal detachment repair within 28 days of symptom onset\n* Patients undergoing vitrectomy or vitrectomy with scleral buckle\n\nExclusion criteria:\n\n* Patient unable to give consent\n* Patient unable to follow-up\n* Prior history of retinal detachment incisional surgery in presenting eye\n* Prior history of open globe injury to presenting eye\n* Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery, actively on glaucoma medication\n* Prior history of corneal disease, or history of corneal edema\n* Patient already on topical netarsudil in presenting eye\n* Patient without natural lens or intraocular lens implant (I.e., aphakic patients)\n* Patients with intraocular pressure \\\u003C8mm Hg in operative eye\n* Active or chronic or recurrent uncontrolled ocular or systemic disease\n* Active or history of chronic or recurrent inflammatory eye disease\n* Diagnosis of proliferative diabetic retinopathy\n* Signs of ocular infection at presentation in either eye\n* Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively\n* Inability to use\u002F apply topical eye drops\n\nThe proliferative vitreoretinopathy cohort will have the following selection criteria:\n\nInclusion criteria:\n\n* Patients \\> 18 years old\n* Patient presenting with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma\n* Patients undergoing vitrectomy or vitrectomy with scleral buckle\n\nExclusion criteria:\n\n* Patient unable to give consent\n* Patient unable to follow-up\n* Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery\n* Patient already on topical netarsudil in presenting eye\n* Patients with intraocular pressure \\\u003C8mm Hg in operative eye\n* Active or chronic or recurrent uncontrolled ocular or systemic disease\n* Active or history of chronic or recurrent inflammatory eye disease\n* Diagnosis of severe nonproliferative or proliferative diabetic retinopathy or vasoproliferative disease in operative eye\n* Signs of ocular infection at presentation in either eye\n* Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively\n* Inability to use\u002F apply topical eye drops\n* No Light Perception vision in operative eye\n* Failure to achieve intraoperative reattachment",{"count":135,"type":20},48,[23,137],"PHASE2","This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes.\n\nThe second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.",[28,26],[56,141,142,143,144],"Netarsudil","Pharmacokinetics","Safety","Efficacy","2025-10-24",{"date":147,"type":33},"2025-10-28",{"date":149,"type":33},"2025-01-14",{"date":151,"type":20},"2026-12",{"name":39,"class":40},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":72},"100599242","ham-for-inferior-rrd-100599242","NCT07081945","hAM for Inferior RRD","Prospective Study on the Use of Human Amniotic Membrane (hAM) in the Treatment of Inferior Rhegmatogenous Retinal Detachment (RRD)","Inclusion Criteria:\n\n1. Subjects having given free and informed consent to take part in the study.\n2. Subjects between 18 and 70 years old.\n3. Subjects suffering RRD (both primary and recurrent RRDs) with at least one of these conditions:\n\n   1. inferior retinal breaks between 4- and 8-o'clock within the detached area regardless of PVR grade;\n   2. requiring retinotomy inferiorly between 4- and 8-o'clock (due to severe inferior PVR or inferior retinal shortening).\n\nExclusion Criteria:\n\n1. Subjects with RRD with only anterior retina breaks or dialysis and meet the indications for scleral buckling surgery.\n2. Subjects with RRD whose retinal breaks located between the 4- and 8-o'clock positions and are not involved in the detached area.\n3. Subjects with pre-existing serious eye diseases (corneal ulcers, glaucoma, uveitis, etc).\n4. History of epilepsy or serious psychiatric diseases.\n5. Other conditions that the researcher found improper to be included into this study.",{"count":19,"type":20},[115],"The objective of the study is to evaluate the efficacy of using hAM patches over the retina to seal inferior retinal breaks. The researchers will evaluate whether hAM patch-assisted vitrectomy improves surgical success rate of retinal reattachment.",[28],"2025-07-23",{"date":166,"type":33},"2025-07-28",{"date":168,"type":20},"2025-08-01",{"date":170,"type":20},"2026-07-31",{"name":172,"class":40},"Eye & ENT Hospital of Fudan University",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":191,"locationsCount":72},"100579613","analysis-of-risk-factors-for-high-intraocular-pressure-and-retinal-detachment-recurrence-after-vitrectomy-with-silicone-oil-tamponade-in-retinal-detachment-patients-100579613","NCT06826573","Analysis of Risk Factors for High Intraocular Pressure and Retinal Detachment Recurrence After Vitrectomy with Silicone Oil Tamponade in Retinal Detachment Patients","Inclusion Criteria:\n\n* 1\\. Diagnosed with \"rhegmatogenous retinal detachment\". 2. Aged over 18 years old, with normal mental and psychological status, regardless of gender.\n\n  3\\. Intraocular pressure of both eyes is less than 21 mmHg before surgery, and having no personal or family history of glaucoma.\n\n  4\\. Cup - to - disc ratio (C\u002FD) in fundus examination is less than 0.5 for both eyes.\n\n  5\\. Those who understand the purpose of this study, sign the \"Informed Consent Form\" and have a high degree of compliance.\n\nExclusion Criteria:\n\n\\- 1. Those with high intraocular pressure before surgery and suffering from ophthalmic diseases such as glaucoma; 3. Those with acute or chronic systemic infections and hematological diseases; 4. Those with a history of mental and psychological diseases; 5. Those with incomplete survey data or unable to cooperate with this research. 5. Those with traumatic rhegmatogenous retinal detachment; 6. Those with active ocular infectious lesions in either eye; 7. Those with severe refractive media opacity (such as corneal nebula, corneal leukoma) in the target eye, which affects imaging examinations during postoperative follow - up.\n\n8\\. Those with a history of congenital structural abnormalities in the target eye; 9. Those who have undergone vitrectomy for other vitreoretinal diseases in the target eye before screening; 10. Those whom the researchers consider unfit to participate in this clinical trial.","90 Years",{"count":181,"type":20},65,"OBSERVATIONAL","This study is a retrospective study. Patients who visited the ophthalmology clinic of the First Affiliated Hospital of Chongqing Medical University between September 1, 2024, and December 31, 2025, will be screened according to the inclusion and exclusion criteria mentioned below. After obtaining informed consent, clinical data of the subjects will be collected. The surgical procedure will involve \"vitrectomy + retinal laser photocoagulation + retinal reattachment + silicone oil tamponade (+ cataract extraction + intraocular lens implantation).\" Observation indicators will be recorded at various time points postoperatively: 1 day, 1 week, 1 month, 3 months, 6 months, and before silicone oil removal. Any emergent events occurring during the trial will be treated accordingly. Finally, data will be statistically analyzed to identify risk factors for high intraocular pressure and retinal detachment recurrence in patients with rhegmatogenous retinal detachment.",[28],"2025-02-10",{"date":187,"type":33},"2025-02-14",{"date":189,"type":33},"2024-09-01",{"date":30,"type":20},{"name":192,"class":40},"First Affiliated Hospital of Chongqing Medical University",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":72},"100569439","comparison-of-anatomical-and-functional-outcomes-of-laser-photocoagulation-and-cryopexy-in-patients-with-rhegmatogenous-retinal-detachment-treated-with-pneumatic-retinopexy-100569439","NCT06694259","Comparison of Anatomical and Functional Outcomes of Laser Photocoagulation and Cryopexy in Patients with Rhegmatogenous Retinal Detachment Treated with Pneumatic Retinopexy","Comparison of Anatomical and Functional Outcomes of Laser Photocoagulation and Cryopexy in Patients with Rhegmatogenous Retinal Detachment Treated with Pneumatic Retinopexy: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients with rhegmatogenous retinal detachment with one or more tears within two clock hours, limited to the upper half of the retina\n\nExclusion Criteria:\n\n* Patients with tears in the lower half of the retina\n* Patients with multiple retinal tears covering more than two clock hours\n* Patients with developed proliferative vitreoretinopathy\n* Patients with vitreous hemorrhage\n* Patients with opaque optical media due to other conditions that could obstruct a detailed fundus examination or the procedure itself\n* Patients unable to follow postoperative head positioning instructions\n* Patients under age of 18 years",{"count":201,"type":20},40,[115],"Rhegmatogenous Retinal Detachment is a pathological condition in which the inner layers of the retina separate from its outermost layer due to fluid entering between these layers through a retinal tear. Retinal detachment is one of the most urgent conditions in ophthalmology; if left untreated, it leads to severe vision loss and blindness. The only possible treatment is a surgical procedure to close the tear and reattach the separated retinal layers.\n\nCurrently, three techniques are used for surgically managing retinal detachment with a tear. You will undergo a technique called pneumatic retinopexy. In this procedure, reattachment of the retina is achieved by injecting sulfur hexafluoride gas (SF6) into the vitreous (the gel that fills the eye) about 4 millimeters from the corneal edge, using a very fine needle. The retinal tear is then closed by either freezing (cryotherapy) immediately before the gas injection or by laser photocoagulation after the gas is introduced.\n\nThe procedure will be done under local anesthesia, with the pupil first dilated using eye drops. After the procedure, a combination of antibiotics and corticosteroids will be instilled in the eye, followed by an ointment of the same combination, and the eye will be covered with a sterile dressing. You will need to maintain a specific head position, depending on the location of the retinal tear, for several days while the gas is present in the eye. This position helps the gas press against the tear, allowing it to heal. During this time, you should keep your head elevated, even at night, almost in a sitting position. Since the gas is lighter than the vitreous and rises within the eye, your head position should keep the tear positioned at 12 o'clock so the gas bubble can mechanically close it.\n\nProper patient selection is essential for this procedure: only patients with retinal tears limited to the upper half of the retina, with one or more tears within an hour area of the peripheral retina, are suitable for this technique. The gas does not need to be removed, as it will spontaneously reabsorb over 6-7 days. While it is in your eye, you will see it as a single bubble that will gradually shrink over 6-7 days before disappearing. If you experience severe pain on the first day, notify your surgeon, as gas expansion within the eye could cause a temporary rise in eye pressure in the first 24-48 hours.\n\nYou will need to remain in the same head position at home while the gas is present in your eye. While the gas is in place, you must not fly, as cabin pressure changes could cause the gas to expand. If you are unable to maintain the necessary position, this procedure may not be suitable for you, and an alternative technique would be needed.\n\nThis technique is less invasive than the two other surgical treatments for retinal detachment. It is performed under local anesthesia, is brief, carries fewer risks, and does not require additional follow-up procedures if the surgery is successful, which largely depends on your adherence to postoperative care.",[28],[89,206,207,208],"Pneumatic retinopexy","Transscleral cryopexy","Laser photocoagulation","2024-12-17",{"date":211,"type":33},"2024-12-19",{"date":213,"type":33},"2024-12-18",{"date":215,"type":20},"2025-12",{"name":217,"class":40},"Clinical Hospital Center, Split",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":72},"100563024","foldable-capsular-scleral-buckling-versus-vitrectomy-in-medium-complex-rhegmatogenous-retinal-detachment-treatment-100563024","NCT06610786","Foldable Capsular Scleral Buckling Versus Vitrectomy in Medium-complex Rhegmatogenous Retinal Detachment Treatment","The Use of FCSB in Medium-complex RRD - a Safety and Efficacy Evaluation","FCSB","Inclusion Criteria:\n\nOne or more retinal holes which cannot be treated sufficiently with a single silicon sponge or silicone band (e.g. large holes, multiple holes, multiple holes of varying anterior-posterior localisation, massive traction)\n\nExclusion Criteria\n\n1. simple rhegmatogenous retinal detachment which can be treated with a single silicon sponge or silicone band (e.g. single holes, no traction, limit retinal detachment)\n2. Complicated RRD, including macular hole within the arcade, PVR C or D, severe cataract, severe vitreous hemorrhage, unclear macular hole,\n3. Combined with other eye diseases that affect vision prognosis.\n4. History of other eye surgeries including cataract surgery.\n5. Presence of systemic diseases that may affect postoperative observation and follow-up.","60 Years",{"count":228,"type":20},100,[115],"The objective of the study is to evaluate:\n\n1. Safety and efficacy of a novel foldable capsular scleral buckle (FCSB) in scleral buckling for primary rhegmatogenous retinal detachment (RRD) of medium complexity.\n2. Comparison between FCSB and pars plana vitrectomy in therapeutic effects and complications in the treatment of primary RRD of medium complexity.",[28],"2024-09-20",{"date":234,"type":33},"2024-09-24",{"date":236,"type":20},"2024-12-01",{"date":238,"type":20},"2029-12-01",{"name":172,"class":40},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":72},"100557704","phase-2-prevention-of-proliferative-vitreoretinopathy-with-intravitreal-methotrexate-in-primary-retinal-detachment-repair-fixer-trial-100557704","NCT06541574","Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial","FIXER","Inclusion Criteria:\n\n• Any adult patient, age \\> 18 years-old, undergoing primary rhegmatogenous retinal detachment surgery with pars plana vitrectomy at the Cincinnati Eye Institute in Blue Ash, Ohio who is able to give informed consent.\n\nExclusion Criteria:\n\n* Age \\<18 years-old\n* Pregnant patients or patients of child bearing potential unwilling to utilize long term contraception for the 12-week period spanning vitrectomy surgery for retinal detachment repair up until the 3 month postoperative visit.\n* History of endophthalmitis, ruptured globe or significant trauma in the affected eye\n* Chronic retinal detachment (symptoms \\> six weeks)\n* Any previous previous retinal detachment repair with pars plana vitrectomy, or scleral buckling surgery. Patients having undergone previous pneumatic retinopexy will not be excluded.\n* Presence of Grade C PVR: full thickness retinal folds or subretinal bands\n* Patients with contraindications to methotrexate, including breastfeeding, pregnancy, attempting to conceive a child or any known hypersensitivity or intolerance to methotrexate\n* Patients with diminished mental capacity precluding their ability to give informed consent.",{"count":248,"type":20},860,[137],"I. Title Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial\n\n* Today's Date: September 18, 2023 II. Principal Investigator\n* Principal Investigator: Christopher D. Riemann, M.D. (Cincinnati Eye Institute)\n* Email: criemann@cvphealth.com, Phone: 513-708-1979\n\nV. Research Summary\n\nPurpose:\n\nTo evaluate methotrexate for the prevention of PVR after primary rhegmatogenous retinal detachment repair.\n\nMethods:\n\nInclusion Criteria:\n\n• Any adult patient, age ≥18 years-old, undergoing primary rhegmatogenous retinal detachment surgery with pars plana vitrectomy at the Cincinnati Eye Institute in Blue Ash, Ohio who is able to give informed consent.\n\nExclusion Criteria:\n\n* Age \\<18 years old\n* Pregnant patients or patients of child bearing potential unwilling to utilize long term contraception for the 12-week period spanning vitrectomy surgery for retinal detachment repair up until the 3 month postoperative visit.\n* History of endophthalmitis, ruptured globe or significant trauma in the affected eye\n* Chronic retinal detachment (symptoms greater than or equal to six weeks)\n* Any previous previous retinal detachment repair with pars plana vitrectomy, or scleral buckling surgery. Patients having undergone previous pneumatic retinopexy will not be excluded.\n* Presence of Grade C PVR: full thickness retinal folds or subretinal bands\n* Patients with contraindications to methotrexate, including breastfeeding, pregnancy, attempting to conceive a child or any known hypersensitivity or intolerance to methotrexate\n* Patients with diminished mental capacity precluding their ability to give informed consent.\n\nStudy Design and Randomization This prospective double masked trial will randomize patients into four groups in a 1:1:1:1 fashion. All attending surgeons and patients will be masked to group randomization. Randomization into four groups will occur on the day of surgery by the Cincinnati Eye Institute's pharmacist, Deepali Chachare. Group A will consist of ≥ 150 patients receiving intraoperative infusion with balanced salt solution containing methotrexate (40mg\u002F500mL BSS), and methotrexate intravitreal injections (400mcg\u002F0.05mL) at postoperative weeks 1, 3, 6, and 10. Group B will consist of ≥ 150 patients receiving intraoperative balanced salt solution infusion containing methotrexate, and sham intravitreal injections at postoperative weeks 1, 3, 6, and 10. Group C will consist of ≥ 150 patients receiving a balanced salt solution infusion without methotrexate, and methotrexate injections at postoperative weeks 1, 3, 6, and 10. Group D will consist of ≥ 150 patients receiving intraoperative balanced salt solution infusion without methotrexate, and sham intravitreal injections at postoperative weeks 1, 3, 6, and 10.",[26,28],[26,28],"2024-09-05",{"date":255,"type":33},"2024-09-19",{"date":257,"type":33},"2024-03-01",{"date":259,"type":20},"2026-06",{"name":261,"class":40},"Cincinnati Eye Institute, Southwest Ohio"]